GlycA, a novel inflammatory marker, is associated with subclinical coronary disease

Martin Tibuakuu, Oluwaseun E. Fashanu, Di Zhao, James D. Otvos, Todd T Brown, Sabina Haberlen, Eliseo Guallar, Matthew J. Budoff, Frank J. Palella, Jeremy J. Martinson, Akintunde O. Akinkuolie, Samia Mora, Wendy S Post, Erin Donnelly Michos

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS). DESIGN: Cross-sectional analysis of 935 men with plasma measurement of GlycA and noncontrast cardiac computed tomography (CT) and/or coronary CT angiography. METHODS: We used multivariable Poisson and linear regression to assess associations of GlycA with prevalent coronary atherosclerosis and plaque extent, respectively. RESULTS: Mean ± SD age was 54 ± 7 years; 31% were black; 63% HIV-infected. GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397 ± 68 vs. 380 ± 60 μmol/l, P = 0.0001) and higher for men with detectable viral load vs. undetectable (413 ± 79 vs. 393 ± 65 μmol/l, P = 0.004). After adjusting for HIV serostatus, demographic and CVD risk factors, every 1SD increment in GlycA level was associated with a higher prevalence of coronary artery calcium (CAC >0) [prevalence ratio 1.09 (95% CI 1.03-1.15)] and coronary stenosis at least 50% [1.20 (1.02-1.41)]. These associations were not significantly altered after adjusting for traditional inflammatory biomarkers or differ by HIV serostatus. Among men with plaque, GlycA was positively associated with the extent of CAC and total plaque. CONCLUSION: HIV infection was associated with higher GlycA levels. In both HIV-infected and HIV-uninfected individuals, GlycA was significantly associated with several measures of subclinical coronary atherosclerosis, independent of other CVD risk factors and inflammatory biomarkers. These findings suggest the potential role of GlycA in CVD risk stratification among HIV patients.

Original languageEnglish (US)
Pages (from-to)547-557
Number of pages11
JournalAIDS (London, England)
Volume33
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Coronary Disease
HIV
Cardiovascular Diseases
Biomarkers
Coronary Artery Disease
Coronary Stenosis
Viral Load
HIV Infections
Linear Models
Coronary Vessels
Acquired Immunodeficiency Syndrome
Cohort Studies
Cross-Sectional Studies
Tomography
Demography
Inflammation
Calcium

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. / Tibuakuu, Martin; Fashanu, Oluwaseun E.; Zhao, Di; Otvos, James D.; Brown, Todd T; Haberlen, Sabina; Guallar, Eliseo; Budoff, Matthew J.; Palella, Frank J.; Martinson, Jeremy J.; Akinkuolie, Akintunde O.; Mora, Samia; Post, Wendy S; Michos, Erin Donnelly.

In: AIDS (London, England), Vol. 33, No. 3, 01.03.2019, p. 547-557.

Research output: Contribution to journalArticle

Tibuakuu, Martin ; Fashanu, Oluwaseun E. ; Zhao, Di ; Otvos, James D. ; Brown, Todd T ; Haberlen, Sabina ; Guallar, Eliseo ; Budoff, Matthew J. ; Palella, Frank J. ; Martinson, Jeremy J. ; Akinkuolie, Akintunde O. ; Mora, Samia ; Post, Wendy S ; Michos, Erin Donnelly. / GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. In: AIDS (London, England). 2019 ; Vol. 33, No. 3. pp. 547-557.
@article{97da8b661a85468bbdad9237bcd494ba,
title = "GlycA, a novel inflammatory marker, is associated with subclinical coronary disease",
abstract = "OBJECTIVE: GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS). DESIGN: Cross-sectional analysis of 935 men with plasma measurement of GlycA and noncontrast cardiac computed tomography (CT) and/or coronary CT angiography. METHODS: We used multivariable Poisson and linear regression to assess associations of GlycA with prevalent coronary atherosclerosis and plaque extent, respectively. RESULTS: Mean ± SD age was 54 ± 7 years; 31{\%} were black; 63{\%} HIV-infected. GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397 ± 68 vs. 380 ± 60 μmol/l, P = 0.0001) and higher for men with detectable viral load vs. undetectable (413 ± 79 vs. 393 ± 65 μmol/l, P = 0.004). After adjusting for HIV serostatus, demographic and CVD risk factors, every 1SD increment in GlycA level was associated with a higher prevalence of coronary artery calcium (CAC >0) [prevalence ratio 1.09 (95{\%} CI 1.03-1.15)] and coronary stenosis at least 50{\%} [1.20 (1.02-1.41)]. These associations were not significantly altered after adjusting for traditional inflammatory biomarkers or differ by HIV serostatus. Among men with plaque, GlycA was positively associated with the extent of CAC and total plaque. CONCLUSION: HIV infection was associated with higher GlycA levels. In both HIV-infected and HIV-uninfected individuals, GlycA was significantly associated with several measures of subclinical coronary atherosclerosis, independent of other CVD risk factors and inflammatory biomarkers. These findings suggest the potential role of GlycA in CVD risk stratification among HIV patients.",
author = "Martin Tibuakuu and Fashanu, {Oluwaseun E.} and Di Zhao and Otvos, {James D.} and Brown, {Todd T} and Sabina Haberlen and Eliseo Guallar and Budoff, {Matthew J.} and Palella, {Frank J.} and Martinson, {Jeremy J.} and Akinkuolie, {Akintunde O.} and Samia Mora and Post, {Wendy S} and Michos, {Erin Donnelly}",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/QAD.0000000000002079",
language = "English (US)",
volume = "33",
pages = "547--557",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - GlycA, a novel inflammatory marker, is associated with subclinical coronary disease

AU - Tibuakuu, Martin

AU - Fashanu, Oluwaseun E.

AU - Zhao, Di

AU - Otvos, James D.

AU - Brown, Todd T

AU - Haberlen, Sabina

AU - Guallar, Eliseo

AU - Budoff, Matthew J.

AU - Palella, Frank J.

AU - Martinson, Jeremy J.

AU - Akinkuolie, Akintunde O.

AU - Mora, Samia

AU - Post, Wendy S

AU - Michos, Erin Donnelly

PY - 2019/3/1

Y1 - 2019/3/1

N2 - OBJECTIVE: GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS). DESIGN: Cross-sectional analysis of 935 men with plasma measurement of GlycA and noncontrast cardiac computed tomography (CT) and/or coronary CT angiography. METHODS: We used multivariable Poisson and linear regression to assess associations of GlycA with prevalent coronary atherosclerosis and plaque extent, respectively. RESULTS: Mean ± SD age was 54 ± 7 years; 31% were black; 63% HIV-infected. GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397 ± 68 vs. 380 ± 60 μmol/l, P = 0.0001) and higher for men with detectable viral load vs. undetectable (413 ± 79 vs. 393 ± 65 μmol/l, P = 0.004). After adjusting for HIV serostatus, demographic and CVD risk factors, every 1SD increment in GlycA level was associated with a higher prevalence of coronary artery calcium (CAC >0) [prevalence ratio 1.09 (95% CI 1.03-1.15)] and coronary stenosis at least 50% [1.20 (1.02-1.41)]. These associations were not significantly altered after adjusting for traditional inflammatory biomarkers or differ by HIV serostatus. Among men with plaque, GlycA was positively associated with the extent of CAC and total plaque. CONCLUSION: HIV infection was associated with higher GlycA levels. In both HIV-infected and HIV-uninfected individuals, GlycA was significantly associated with several measures of subclinical coronary atherosclerosis, independent of other CVD risk factors and inflammatory biomarkers. These findings suggest the potential role of GlycA in CVD risk stratification among HIV patients.

AB - OBJECTIVE: GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS). DESIGN: Cross-sectional analysis of 935 men with plasma measurement of GlycA and noncontrast cardiac computed tomography (CT) and/or coronary CT angiography. METHODS: We used multivariable Poisson and linear regression to assess associations of GlycA with prevalent coronary atherosclerosis and plaque extent, respectively. RESULTS: Mean ± SD age was 54 ± 7 years; 31% were black; 63% HIV-infected. GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397 ± 68 vs. 380 ± 60 μmol/l, P = 0.0001) and higher for men with detectable viral load vs. undetectable (413 ± 79 vs. 393 ± 65 μmol/l, P = 0.004). After adjusting for HIV serostatus, demographic and CVD risk factors, every 1SD increment in GlycA level was associated with a higher prevalence of coronary artery calcium (CAC >0) [prevalence ratio 1.09 (95% CI 1.03-1.15)] and coronary stenosis at least 50% [1.20 (1.02-1.41)]. These associations were not significantly altered after adjusting for traditional inflammatory biomarkers or differ by HIV serostatus. Among men with plaque, GlycA was positively associated with the extent of CAC and total plaque. CONCLUSION: HIV infection was associated with higher GlycA levels. In both HIV-infected and HIV-uninfected individuals, GlycA was significantly associated with several measures of subclinical coronary atherosclerosis, independent of other CVD risk factors and inflammatory biomarkers. These findings suggest the potential role of GlycA in CVD risk stratification among HIV patients.

UR - http://www.scopus.com/inward/record.url?scp=85060885027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060885027&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000002079

DO - 10.1097/QAD.0000000000002079

M3 - Article

C2 - 30475263

AN - SCOPUS:85060885027

VL - 33

SP - 547

EP - 557

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 3

ER -